Vertex Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Vertex Pharmaceuticals Inc cash flow-to-debt ratio. Vertex Pharmaceuticals Inc (VRTX) has a Cash Flow-to-Debt Ratio of 0.16x as of June 2026, meaning its operating cash flow of $1.13 Billion could theoretically repay 0% of its total liabilities ($7.18 Billion) in one year. Check VRTX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Vertex Pharmaceuticals Inc (1991–2025)
Cash flow-to-debt ratio of Vertex Pharmaceuticals Inc from 1991 to 2025. Historical debt coverage capacity for Vertex Pharmaceuticals Inc across 35 annual periods. Check cash flow reinvestment rate of Vertex Pharmaceuticals Inc to assess the company's total reinvestment commitment from operating cash flow.
Vertex Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (1991–2025)
Vertex Pharmaceuticals Inc cash flow-to-debt ratio by year from 1991 to 2025. Year-by-year debt coverage analysis for Vertex Pharmaceuticals Inc. For the full cash flow conversion analysis, see VRTX operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.49x | $3.63 Billion | $7.48 Billion | ▲ +703.8% |
| 2024 | -0.08x | $-492.60 Million | $6.12 Billion | ▼ -111.7% |
| 2023 | 0.69x | $3.54 Billion | $5.15 Billion | ▼ -29.5% |
| 2022 | 0.97x | $4.13 Billion | $4.24 Billion | ▲ +22.8% |
| 2021 | 0.79x | $2.64 Billion | $3.33 Billion | ▼ -25.3% |
| 2020 | 1.06x | $3.25 Billion | $3.06 Billion | ▲ +51.1% |
| 2019 | 0.70x | $1.57 Billion | $2.23 Billion | ▲ +0.2% |
| 2018 | 0.70x | $1.27 Billion | $1.81 Billion | ▲ +24.9% |
| 2017 | 0.56x | $844.94 Million | $1.50 Billion | ▲ +270.2% |
| 2016 | 0.15x | $236.10 Million | $1.56 Billion | ▲ +158.3% |
| 2015 | -0.26x | $-365.43 Million | $1.40 Billion | ▲ +37.2% |
| 2014 | -0.41x | $-513.20 Million | $1.24 Billion | ▼ -673.5% |
| 2013 | -0.05x | $-51.57 Million | $962.64 Million | ▼ -130.5% |
| 2012 | 0.18x | $267.84 Million | $1.52 Billion | ▲ +51.4% |
| 2011 | 0.12x | $143.74 Million | $1.24 Billion | ▲ +122.3% |
| 2010 | -0.52x | $-635.44 Million | $1.22 Billion | ▼ -4.5% |
| 2009 | -0.50x | $-427.59 Million | $859.14 Million | ▼ -63.0% |
| 2008 | -0.31x | $-226.48 Million | $741.61 Million | ▲ +60.1% |
| 2007 | -0.76x | $-252.48 Million | $330.18 Million | ▼ -1314.1% |
| 2006 | -0.05x | $-22.48 Million | $415.64 Million | ▲ +90.3% |
| 2005 | -0.56x | $-172.05 Million | $309.82 Million | ▼ -99.2% |
| 2004 | -0.28x | $-142.16 Million | $510.01 Million | ▲ +11.6% |
| 2003 | -0.32x | $-167.62 Million | $531.57 Million | ▼ -73.3% |
| 2002 | -0.18x | $-79.54 Million | $437.14 Million | ▼ -913.6% |
| 2001 | -0.02x | $-8.07 Million | $449.78 Million | ▲ +53.9% |
| 2000 | -0.04x | $-16.64 Million | $427.12 Million | ▲ +97.2% |
| 1999 | -1.37x | $-31.80 Million | $23.21 Million | ▲ +11.5% |
| 1998 | -1.55x | $-31.10 Million | $20.10 Million | ▼ -222.6% |
| 1997 | -0.48x | $-9.40 Million | $19.60 Million | ▲ +84.9% |
| 1996 | -3.17x | $-40.30 Million | $12.70 Million | ▼ -171.7% |
| 1995 | -1.17x | $-16.00 Million | $13.70 Million | ▲ +15.0% |
| 1994 | -1.37x | $-14.70 Million | $10.70 Million | ▼ -283.7% |
| 1993 | 0.75x | $8.60 Million | $11.50 Million | ▲ +200.2% |
| 1992 | -0.75x | $-5.30 Million | $7.10 Million | ▼ -46.3% |
| 1991 | -0.51x | $-2.50 Million | $4.90 Million | — |